Učitavanje...
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
BACKGROUND: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in...
Spremljeno u:
| Izdano u: | Ther Adv Med Oncol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7278098/ https://ncbi.nlm.nih.gov/pubmed/32550862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920915303 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|